Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury

Drug

General health

Online since 5 October 2024, updated 60 days ago

About this trial

This phase I trial is enrolling 36 participants with chronic spinal cord injury to assess the safety, tolerability, and effect of a drug - EC5026 - on neuropathic pain. If included, participants will be randomly assigned to receive the drug or a placebo once daily for 14 consecutive days. Final testing of safety, tolerability, and changes in pain will be performed after 30 days.

Included participants

Gender

All

Age

≥ 18 years

Injury level

C2 - T12

Severity (AIS)?

Time since injury

≥ 12 months

Healthy volunteers

C2-T12

Additionally, participants must

NOT have other chronic neuropathic pain conditions, including painful diabetic neuropathy, HIV-associated neuropathic pain, chemotherapy or ethanol-associated neuropathy.

be United States veterans

What’s involved

Type

Drug

Details

- Participants will receive a drug (EC5026) or a placebo once daily for 14 consecutive days. - Final testing of safety and tolerability will be performed after 30 days.

Potential benefits

Main benefits

General health

Additional benefits

Pain

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results